{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:17:52Z","timestamp":1776453472370,"version":"3.51.2"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T00:00:00Z","timestamp":1127260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Abnormalities in the <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> gene have been reported in several human malignancies, including nonsmall cell lung carcinoma (NSCLC). Aberrant methylation of the <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> promoter also has been reported in NSCLC, but its clinical significance remains to be elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors studied <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation in 305 patients with NSCLC to gain a further understanding of the clinicopathologic and prognostic significance of <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation in patients with NSCLC. The methylation status of the <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> gene was investigated by using methylation\u2010specific polymerase chain reaction analysis in paraffin blocks from 305 patients with NSCLC. Ki\u201067 expression was assessed by immunohistochemical staining. All statistical analyses were 2\u2010sided with a 5% Type I error rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p><jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation was observed in 130 of 305 tumor samples (43%). The prevalence of <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation was associated significantly with pathologic stage and was observed in 44% of patients with Stage I disease, in 23% of patients with Stage II disease, in 59% of patients with Stage III, and in 88% of patients with Stage IV disease (<jats:italic>P<\/jats:italic> = 0.001). <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation occurred with a 2.71 times greater prevalence (95% confidence interval [95% CI], 1.21\u20136.09; <jats:italic>P<\/jats:italic> = 0.01) T2 tumors than in T1 tumors and with a 3.78\u2010fold greater prevalence (95% CI, 1.05\u201313.59; <jats:italic>P<\/jats:italic> = 0.04) in T3 tumors than in T1 tumors. However, lymph node metastasis was related inversely with <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation (odds ratio = 0.51; 95% CI, 0.28\u20130.95; <jats:italic>P<\/jats:italic> = 0.03), and <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation was not associated with the Ki\u201067 labeling index (<jats:italic>P<\/jats:italic> = 0.53) or with tumor size (<jats:italic>P<\/jats:italic> = 0.89). No relation was found between <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation and survival in patients with Stage I NSCLC (<jats:italic>P<\/jats:italic> = 0.51) or in patients with Stage II NSCLC (<jats:italic>P<\/jats:italic> = 0.46).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current findings suggested an association between <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation and tumor progression in NSCLC but had no prognostic significance in patients with early\u2010stage NSCLC. In addition, <jats:italic>H<\/jats:italic>\u2010<jats:italic>cadherin<\/jats:italic> methylation may be a valuable candidate molecular marker for the early detection of NSCLC. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21409","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T12:19:19Z","timestamp":1127305159000},"page":"1825-1833","source":"Crossref","is-referenced-by-count":61,"title":["Aberrant methylation of <i>H<\/i>\u2010<i>cadherin<\/i> (<i>CDH13<\/i>) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma"],"prefix":"10.1002","volume":"104","author":[{"given":"Jin","family":"Seuk Kim","sequence":"first","affiliation":[]},{"given":"Joungho","family":"Han","sequence":"additional","affiliation":[]},{"given":"Young Mog","family":"Shim","sequence":"additional","affiliation":[]},{"given":"Joobae","family":"Park","sequence":"additional","affiliation":[]},{"given":"Duk\u2010Hwan","family":"Kim","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2005,9,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211123272006"},{"key":"e_1_2_6_3_2","first-page":"83S","article-title":"Lung cancer screening: an update","volume":"19","author":"Marcus PM","year":"2001","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2006419"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0955-0674(93)90029-P"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01833258"},{"key":"e_1_2_6_7_2","first-page":"1287","article-title":"Recent progress in T\u2010cadherin (CDH13, H\u2010cadherin) research","volume":"16","author":"Takeuchi T","year":"2001","journal-title":"Histol Histopathol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-776"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/19.6.1157"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050790"},{"key":"e_1_2_6_11_2","first-page":"4556","article-title":"Loss of expression and aberrant methylation of the CDH13 (H\u2010cadherin) gene in breast and lung carcinomas","volume":"61","author":"Toyooka KO","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_6_12_2","first-page":"1683","article-title":"Loss of H\u2010cadherin protein expression in human non\u2010small cell lung cancer is associated with tumorigenicity","volume":"7","author":"Zhong Y","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10787"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60702-2"},{"key":"e_1_2_6_15_2","first-page":"61","article-title":"DNA methylation profiles of lung tumors","volume":"1","author":"Toyooka KO","year":"2001","journal-title":"Mol Cancer Therapeutics."},{"key":"e_1_2_6_16_2","first-page":"177","article-title":"DNA methylation of multiple genes and clinicopathological relationship of non\u2010small cell lung cancers","volume":"12","author":"Hanabata T","year":"2004","journal-title":"Oncol Rep."},{"key":"e_1_2_6_17_2","first-page":"249","article-title":"Aberrant promoter methylation of multiple genes in non\u2010small cell lung cancers","volume":"61","author":"Zochbauer\u2010Muller S","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9821"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.077"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.4.9703099"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.2.566-578.2003"},{"key":"e_1_2_6_22_2","first-page":"1573","article-title":"Exogenous expression of H\u2010cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression","volume":"24","author":"Zhong Y","year":"2004","journal-title":"Int J Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20144"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602013"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:30:06Z","timestamp":1760272206000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,21]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1002\/cncr.21409"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21409","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,21]]}}}